Alnylam's genetic disease drug succeeds key study, shares soar

(Reuters) - Alnylam Pharmaceuticals Inc's drug to treat a rare genetic disease cleared a key study, moving the company closer to filing a marketing application for the drug, which is part of a new class of medicines that block disease-causing proteins.